Trials / Completed
CompletedNCT00195546
Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 465 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Primary: To assess the efficacy and safety of DVS-233 SR compared with placebo for treatment of vasomotor symptoms (VMS) associated with menopause and to compare the bleeding incidence of DVS-233 SR and tibolone. Secondary: To assess the effects of DVS-233 SR and tibolone on changes from baseline in weight, breast pain, and health outcomes indicators.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DVS-233 |
Timeline
- Start date
- 2005-04-01
- Completion
- 2006-01-01
- First posted
- 2005-09-19
- Last updated
- 2007-06-01
Locations
41 sites across 15 countries: Belgium, Croatia, Czechia, Finland, France, Hungary, Mexico, Netherlands, Poland, Romania, South Africa, Spain, Sweden, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00195546. Inclusion in this directory is not an endorsement.